Alnylam's First-Half Sales Surge 89% to $801.9M While Stock Slumps 0.41% on $290M Volume Slump to 341st Rank

Alnylam Pharmaceuticals (ALNY) closed on August 28, 2025, with a 0.41% decline, trading at $451.00. The stock recorded a trading volume of $290 million, a 29.17% drop from the previous day, ranking it 341st in market activity.

Amvuttra (vutrisiran), Alnylam’s flagship RNAi therapy, drove $801.9 million in global sales during the first half of 2025, reflecting 89% year-over-year growth. The drug’s label was expanded to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM) in the U.S. and EU, positioning it as the first and only RNAi therapy approved for both ATTR-CM and polyneuropathy (hATTR-PN). This expansion is expected to sustain demand, with further approvals in other regions anticipated this year.

Competition remains intense in the ATTR-CM market. Pfizer’s Vyndaqel/Vyndamax and BridgeBio’s Attruby offer oral administration and lower U.S. pricing, potentially influencing prescribing patterns. Vyndaqel’s global sales hit $3.1 billion in H1 2025, while Attruby reported $108.2 million in revenue. Alnylam’s higher list prices and delivery method may pose challenges despite Amvuttra’s clinical differentiation.

Valuation metrics highlight Alnylam’s premium pricing, with a price/sales ratio of 24.10, well above the industry average of 2.12. Analysts have raised 2025 earnings estimates from $0.93 to $3.39 per share over 60 days, reflecting confidence in Amvuttra’s growth potential.

Query limit exceeded.